MREO
Mereo BioPharma Group PLC ADR
NASDAQ: MREO · HEALTHCARE · BIOTECHNOLOGY
$0.27
-2.89% today
Updated 2026-04-30
Market cap
$44.72M
P/E ratio
—
P/S ratio
89.45x
EPS (TTM)
$-0.25
Dividend yield
—
52W range
$0 – $3
Volume
1.6M
Mereo BioPharma Group PLC ADR (MREO) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
—
Most recent quarter
EPS YoY growth
+100.0%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-0.6%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+3.9%
2025-11-10
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-04-01 | $0.00 | +100.0% | $0.33 | $0.32 | -3.0% |
| 2026-03-19 | $-0.01 | -7.1% | $0.35 | $0.34 | -2.8% |
| 2025-11-10 | $-0.01 | -175.2% | $1.80 | $1.87 | +3.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $-0.01 | $0.00 | +100.0% | — | — |
| 2025-12-31 | $-0.01 | $-0.01 | -7.1% | — | — |
| 2025-09-30 | $0.01 | $-0.01 | -175.2% | — | — |
| 2025-06-30 | $-0.02 | $-0.02 | +17.7% | $500000.00 | — |
| 2025-03-31 | $-0.01 | $-0.02 | -37.3% | — | — |
| 2024-12-31 | $-0.01 | $-0.01 | +0.0% | $1.06M | +6.4% |
| 2024-09-30 | $-0.02 | $-0.02 | +0.0% | — | — |
| 2024-06-30 | $-0.01 | $-0.09 | -762.0% | — | — |
| 2024-03-31 | $-0.01 | $-0.06 | -539.0% | — | — |
| 2023-12-31 | $-0.02 | $-0.02 | +25.0% | $1.00M | — |
| 2023-09-30 | $0.00 | $0.00 | — | $533429.00 | — |
Frequently asked questions
Has Mereo BioPharma Group PLC ADR beaten earnings estimates?
Mereo BioPharma Group PLC ADR has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports.
How does MREO stock react to earnings?
MREO stock has moved an average of -0.6% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.